Black Diamond (BDTX) CEO awarded 600K stock options at $2.57 strike

Rhea-AI Filing Summary

Black Diamond Therapeutics President and CEO Mark A. Velleca reported a new stock option grant. On January 21, 2026, he was awarded a stock option to buy 600,000 shares of Black Diamond Therapeutics common stock at an exercise price of $2.57 per share. According to the vesting terms, 25% of the shares under this option will vest and become exercisable on January 21, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, conditioned on his continued service with the company. Following this grant, he beneficially owns 600,000 derivative securities in the form of this option, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Velleca Mark A.

(Last) (First) (Middle)

C/O BLACK DIAMOND THERAPEUTICS, INC.

245 FIRST STREET, 18TH FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT & CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.57	01/21/2026		A		600,000		(1)	01/20/2036	Common Stock	600,000	$0	600,000	D

Explanation of Responses:

1. 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Brent Hatzis-Schoch, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BDTX report for Mark A. Velleca?

Black Diamond Therapeutics reported that President & CEO Mark A. Velleca received a grant of a stock option to buy 600,000 shares of common stock on January 21, 2026.

What is the exercise price of the new BDTX stock options granted to the CEO?

The stock option granted to the CEO has an exercise price of $2.57 per share for the underlying Black Diamond Therapeutics common stock.

How do the 600,000 BDTX CEO stock options vest?

25% of the option shares vest and become exercisable on January 21, 2027. The remaining shares vest in 36 equal monthly installments after that date, subject to his continued service.

When do the newly granted BDTX CEO stock options expire?

The stock option granted to the CEO has an expiration date of January 20, 2036, as disclosed in the derivative securities table.

How many BDTX derivative securities does the CEO hold after this transaction?

After the reported grant, Mark A. Velleca beneficially owns 600,000 derivative securities in the form of this stock option, held directly.

Is this BDTX CEO stock option grant a purchase or an award?

The filing shows transaction code "A", indicating an award of a stock option rather than an open-market purchase, with a $0 price for the derivative security at grant.